Zoledronic acid for the prevention of osteoporosis in osteopenic patients undergoing allogeneic HCT

Trial Profile

Zoledronic acid for the prevention of osteoporosis in osteopenic patients undergoing allogeneic HCT

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2012 New trial record
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2012 Primary endpoint 'Lumbar-spine-bone-mineral-density' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top